Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Non-Current Assets (2016 - 2025)

UroGen Pharma's Non-Current Assets history spans 10 years, with the latest figure at $14.4 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 50.7% year-over-year to $14.4 million; the TTM value through Dec 2025 reached $53.2 million, up 130.22%, while the annual FY2025 figure was $14.4 million, 50.7% up from the prior year.
  • Non-Current Assets reached $14.4 million in Q4 2025 per URGN's latest filing, down from $16.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $17.0 million in Q1 2023 to a low of $2.9 million in Q2 2024.
  • Average Non-Current Assets over 5 years is $9.3 million, with a median of $9.3 million recorded in 2021.
  • Peak YoY movement for Non-Current Assets: plummeted 90.39% in 2021, then skyrocketed 311.28% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $5.4 million in 2021, then grew by 25.32% to $6.7 million in 2022, then skyrocketed by 35.95% to $9.1 million in 2023, then rose by 4.94% to $9.6 million in 2024, then skyrocketed by 50.7% to $14.4 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Non-Current Assets are $14.4 million (Q4 2025), $16.5 million (Q3 2025), and $11.8 million (Q2 2025).